We came across a bullish thesis on Amgen Inc. (AMGN) on Disruptive analytics’ Substack by Magnus Ofstad. In this article, we ...
The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...
Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback